Comera Life Sciences Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore™ Platform
WOBURN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) — Comera Life Sciences Holdings, Inc. (Nasdaq:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced a significant expansion of its SQore™ patent portfolio with the issuance of four new patents and two new notices of allowance. The six new patents, three issued in the United States and three covering Canada, Korea and India expand the number of proprietary viscosity reducing excipients in Comera’s SQore platform and significantly broaden claims covered by previously issued patents.
Related news for (CMRA)
- Comera Life Sciences Announces Process Exploring Strategic Alternatives
- Comera Life Sciences Announces Process Exploring Strategic Alternatives
- Comera Life Sciences Appoints Dorothy Clarke to Board of Directors
- Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights
- Comera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery Conference
